Literature DB >> 16528673

Prognostic value of bronchioloalveolar carcinoma component in lung adenocarcinoma.

D-M Lin1, Y Ma, S Zheng, X-Y Liu, S-M Zou, W-Q Wei.   

Abstract

BAC is a common pattern in conventional lung adenocarcinoma. In the past, however, there were no well-defined criteria for BAC. As a result, it was difficult to evaluate the prognosis on this type of lung adenocarcinoma. Though the 1999 WHO classification of BAC provides a useful framework, it does not provide detailed enough information to predict prognosis in lung adenocarcinomas with BAC feature. The aim of this study was to address the prognostic value of bronchioloalveolar carcinoma (BAC) component in lung adenocarcinoma. Ninety-one consecutive surgically treated patients with adenocarcinoma exhibiting various degrees of BAC features and complete follow-up records were retrospectively studied. According to the percentage of BAC component designed as less than 50%, 50%-79%, 80%-99%, and 100%, tumors were classified as type I, type II, type III, and type IV respectively. The overall 5-year survival rate was 64.84%. Multivariate analysis revealed that the four classified types are independent prognostic factors (P=0.0008), as is tumor stage (P=0.0000). The 5-year survival rates were 39.29%, 58.82%, 81.25%, 85.71% for the four classified types respectively, and were 88.89% for stage I, 46.15% for stage II, and 23.81% for stage III. However, the size of tumor (>2 cm) was significant only in the univariate analysis (P=0.0275). In the patients with tumor size exceeding 2 cm in diameter, the BAC component was also significant to predict prognosis (p=0.0008). In lung adenocarcinoma, the BAC component may prove to be useful to predict the outcome of the patients, and the percentage of BAC pattern and pathological stage appear to be two independent prognostic factors.

Entities:  

Mesh:

Year:  2006        PMID: 16528673     DOI: 10.14670/HH-21.627

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  8 in total

Review 1.  Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts.

Authors:  Ming-Ching Lee; Kyuichi Kadota; Daniel Buitrago; David R Jones; Prasad S Adusumilli
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 2.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

3.  Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma.

Authors:  Junji Tsurutani; Seth M Steinberg; Marc Ballas; Matthew Robertson; Jaclyn LoPiccolo; Hiroshi Soda; Shigeru Kohno; Valgardur Egilsson; Phillip A Dennis
Journal:  Lung Cancer       Date:  2006-11-13       Impact factor: 5.705

4.  Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications.

Authors:  Madeline Vazquez; Darryl Carter; Elizabeth Brambilla; Adi Gazdar; Masayuki Noguchi; William D Travis; Yao Huang; Lijuan Zhang; Rowena Yip; David F Yankelevitz; Claudia I Henschke
Journal:  Lung Cancer       Date:  2008-10-31       Impact factor: 5.705

5.  Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease.

Authors:  Kyuichi Kadota; Jonathan Villena-Vargas; Akihiko Yoshizawa; Noriko Motoi; Camelia S Sima; Gregory J Riely; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  Am J Surg Pathol       Date:  2014-04       Impact factor: 6.394

6.  Differential expression of CRKL and AXL genes in lung adenocarcinoma subtypes according to the epidermal growth factor receptor and anaplastic lymphoma kinase gene status.

Authors:  DA-Ping Yu; Yu-Jie Dong; Hai-Qing Zhang; Jing-Hui Wang; Yang Qu; Li-Juan Zhou; Dan Su; Li-Li Zhang; Dan Zhao; Yi-Ran Cai
Journal:  Biomed Rep       Date:  2014-03-20

7.  Association of Stage Shift and Population Mortality Among Patients With Non-Small Cell Lung Cancer.

Authors:  Raja Flores; Parth Patel; Naomi Alpert; Bruce Pyenson; Emanuela Taioli
Journal:  JAMA Netw Open       Date:  2021-12-01

8.  [Interpretation of IASLC/ATS/ERS international multidisciplinary classification of lung neoplasms].

Authors:  Dongmei Lin
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.